The effect of omission of adjuvant radiotherapy after neoadjuvant chemotherapy and breast conserving surgery with a pathologic complete response

References

• Mougalian SS, Soulos PR, Killelea BK, et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer. 2015;121(15):2544–2552.
   PubMed Web of Science ®Google Scholar
• Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Cin Oncol. 1997;15(7):2483–2493.
   PubMed Web of Science ®Google Scholar
• Golshan M, Cirrincione CT, Sikov WM, Alliance for Clinical Trials in Oncology, et al. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Res Treat. 2016;160(2):297–304.
   PubMed Web of Science ®Google Scholar
• Barranger E, Antomarchi J, Chamorey E, et al. Effect of neoadjuvant chemotherapy on the surgical treatment of patients with locally advanced breast cancer requiring initial mastectomy. Clin Breast Cancer. 2015;15(5):e231–e235.
   PubMed Web of Science ®Google Scholar
• Hage AN, Capriccioso C, Brennan J, et al. Impact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancer. J Surg Oncol. 2017;116(6):665–670.
   PubMed Web of Science ®Google Scholar
• Asselain B, Barlow W, Bartlett J, et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27–39.
   PubMed Web of Science ®Google Scholar
• Wang M, Hou L, Chen M, et al. Neoadjuvant chemotherapy creates surgery opportunities for inoperable locally advanced breast cancer. Sci Rep. 2017;7:44673.
   PubMed Web of Science ®Google Scholar
• Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23(12):2694–2702.
   PubMed Web of Science ®Google Scholar
• Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377–384.
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007;13(1):228–233.
   PubMed Web of Science ®Google Scholar
• Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012;30(32):3960–3966.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group; Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–1716.
   PubMed Web of Science ®Google Scholar
• Poortmans PM, Collette S, Kirkove C, EORTC Radiation Oncology and Breast Cancer Groups, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373(4):317–327.
   PubMed Web of Science ®Google Scholar
• Whelan TJ, Olivotto IA, Parulekar WR, MA.20 Study Investigators, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(4):307–316.
   PubMed Web of Science ®Google Scholar
• Boffa DJ, Rosen JE, Mallin K, et al. Using the National Cancer Database for outcomes research: a review. JAMA Oncol. 2017;3(12):1722–1728.
   PubMed Web of Science ®Google Scholar
• Park HS, Gross CP, Makarov DV, et al. Immortal time bias: a frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(5):1365–1373.
   PubMed Web of Science ®Google Scholar
• Sanford RA, Lei X, Giordano SH, et al. Impact of delayed neoadjuvant systemic chemotherapy on survival outcomes in breast cancer patients. J Cin Oncol. 2016;34(15_suppl):1038–1038.
   Web of Science ®Google Scholar
• Network NCC. Breast Cancer (Version 2.2020). [cited 2020 Feb 28] Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf.
   Google Scholar
• R Core Team. R: A language and environment for statistical computing. R foundation for Statistical Computing. 2018. http://finzi.psych.upenn.edu/R/library/dplR/doc/intro-dplR.pdf
   Google Scholar
• von Elm E, Altman DG, Egger M, STROBE Initiative, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–349.
   PubMed Web of Science ®Google Scholar
• Swisher SK, Vila J, Tucker SL, et al. Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapy. Ann Surg Oncol. 2016;23(3):749–756.
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172.
   PubMed Web of Science ®Google Scholar
• Goorts B, van Nijnatten TJA, de Munck L, et al. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2017;163(1):83–91.
   PubMed Web of Science ®Google Scholar
• Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382–2387.
   PubMed Web of Science ®Google Scholar
• Dragun AE, Huang B, Tucker TC, et al. Disparities in the application of adjuvant radiotherapy after breast-conserving surgery for early stage breast cancer: impact on overall survival. Cancer. 2011;117(12):2590–2598.
   PubMed Web of Science ®Google Scholar
• Schroen AT, Brenin DR, Kelly MD, et al. Impact of patient distance to radiation therapy on mastectomy use in early-stage breast cancer patients. J Cin Oncol. 2005;23(28):7074–7080.
   PubMed Web of Science ®Google Scholar
• Celaya MO, Rees JR, Gibson JJ, et al. Travel distance and season of diagnosis affect treatment choices for women with early-stage breast cancer in a predominantly rural population (United States). Cancer Causes Control. 2006;17(6):851–856.
   PubMed Web of Science ®Google Scholar
• Voti L, Richardson LC, Reis IM, et al. Treatment of local breast carcinoma in Florida: the role of the distance to radiation therapy facilities. Cancer. 2006;106(1):201–207.
   PubMed Web of Science ®Google Scholar
• Dawood S, Broglio K, Buzdar A, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Cin Oncol. 2010;28(1):92–98.
   PubMed Web of Science ®Google Scholar
• McGuire SE, Gonzalez-Angulo AM, Huang EH, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007;68(4):1004–1009.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, McGuire SE, Buchholz TA, et al. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Cin Oncol. 2005;23(28):7098–7104.
   PubMed Web of Science ®Google Scholar